CLASS II Drug recall · Reported 18 Dec 2024 · FDA Enforcement Report

Hylenex recombinant (hyaluronidase) injection recalled

Mckesson Medical-Surgical Inc. Corporate Office is recalling Hylenex recombinant (hyaluronidase) injection, 150 USP units/mL, mL Single Dose Vials. The recall was initiated on 11 Sep 2024 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesSerial # 100000831961 100000820688 100000820689 100000820515
NDC18657-117
Quantity recalled5 cartons/20 units each carton

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0116-2025
FDA event ID
95830
Manufacturer
Antares Pharma, Inc.
Classification
Class II
Status
Terminated
Recall initiated
11 Sep 2024
FDA classified
10 Dec 2024
Reported
18 Dec 2024
Type
Voluntary: Firm initiated
Customers notified by
Letter

Timeline

11 Sep 2024Recall initiated by company
10 Dec 2024Classified by FDA+90 days
18 Dec 2024Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

cGMP Deviations: Temperature excursion

Product as listed by the FDA

Hylenex recombinant (hyaluronidase) injection, 150 USP units/mL, 4x1 mL Single Dose Vials, Rx only, Manufactured for and marketed by Halozyme, Inc., 12390 El Camino Real San Diego California 92130, Distributed by Antares Pharma, Inc., Ewing, NJ NDC 18657-117-04

Where it was distributed

Virgina

Questions about this recall

Why was it recalled?

cGMP Deviations: Temperature excursion

Which lots are affected?

Serial # 100000831961 100000820688 100000820689 100000820515

Where was it sold?

Virgina

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Mckesson Medical-Surgical Inc. Corporate Office

All 276

Other Hyaluronidase recalls

All 9